一氧化氮预防斯坦福A型主动脉夹层术后急性肾损伤:随机对照试验研究方案
这项单中心、随机、平行组优效性试验将纳入106例接受急性A型主动脉夹层急诊手术的成人患者,按1:1随机分入体外循环期间及术后12小时吸入60 ppm一氧化氮组或不含一氧化氮的标准治疗组,主要结局为术后48小时内依据KDIGO标准判定的急性肾损伤发生率。
要点
- 单中心随机平行组优效性试验,纳入106例急性A型主动脉夹层急诊手术成人患者,1:1随机分组。
- 干预组在体外循环期间及术后12小时吸入60 ppm一氧化氮,对照组接受不含一氧化氮的标准治疗。
- 主要结局为术后48小时内依据KDIGO标准判定的急性肾损伤发生率。
核心结论
- 该试验将评估围术期一氧化氮给药能否降低高危急性A型主动脉夹层患者的早期急性肾损伤并改善肾脏与临床结局。
- 研究结果可能为主动脉手术中的新型肾脏保护策略提供证据。
研究设计与样本
- 单中心、随机、平行组优效性试验,计划纳入106例接受急性A型主动脉夹层急诊手术的成人患者。
- 参与者按1:1比例随机分入体外循环期间及术后12小时吸入60 ppm一氧化氮组或不含一氧化氮的标准治疗组。
主要发现
- 主要结局为术后48小时内依据KDIGO标准判定的急性肾损伤发生率。
- 次要结局包括急性肾损伤严重程度、尿量、血管活性-正性肌力药物评分、中性粒细胞明胶酶相关脂质运载蛋白水平、序贯器官衰竭评估评分、呼吸机支持时长、重症监护病房与住院时长、主要不良肾脏事件及纵隔与心包引流液累积量。
关键数值与推荐
- 干预方案为体外循环期间及术后12小时吸入60 ppm一氧化氮。
- 急性肾损伤依据KDIGO标准定义,主要结局观察窗为术后48小时。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute kidney injury (AKI) is a frequent and serious complication following surgery for acute type A aortic dissection (ATAAD). Nitric oxide (NO) may reduce AKI incidence through renal-protective mechanisms, but evidence in the ATAAD population remains limited. This trial aims to evaluate whether perioperative administration of NO can reduce the incidence of postoperative AKI in this population. METHODS: This single-center, randomized, parallel-group superiority trial will enroll 106 adult patients undergoing ATAAD emergency surgery. Participants will be randomly allocated in a 1:1 ratio to either receive 60 parts per million of NO during cardiopulmonary bypass and for 12 h post-surgery, or to receive standard care without NO. The primary outcome is AKI incidence within 48 h postoperatively, defined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Secondary outcomes include AKI severity, urine output, vasoactive-inotropic score, neutrophil gelatinase-associated lipocalin levels, sequential organ failure assessment score, ventilator support duration, intensive care unit (ICU) and hospital length of stay, and major adverse kidney events, cumulative mediastinal and pericardial drainage volume. DISCUSSION: This trial will evaluate whether perioperative NO administration can reduce early AKI and improve renal and clinical outcomes in high-risk ATAAD patients. Findings may provide evidence for a novel nephroprotective strategy in aortic surgery. TRIAL REGISTRATION: ClinicalTrials.gov NCT06622291. Registered on June 26, 2024.
引用
- Chen Z, Han X, Li L, et al. Nitric oxide for the prevention of postoperative acute kidney injury in patients undergoing surgery for Stanford type A aortic dissection: study protocol for a randomized controlled trial. Trials. 2025. PMID: 40790609. doi:10.1186/s13063-025-08986-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。